DMT-d4
pharmaceutical compound
DMT-d4, or D4DMT, also known as α,α,β,β-tetradeutero-DMT, is a serotonin receptor modulator and putative psychedelic drug of the tryptamine family related to dimethyltryptamine (DMT). It is the isotopologue of DMT in which the hydrogen atoms at the α and β positions have been replaced with the deuterium isotopes.
Pharmacology
DMT-d4 is thought to be resistant to metabolism by monoamine oxidase (MAO) compared to DMT. Relatedly, D4DMT, at the same dose, shows stronger effects, 2- to 3-fold higher brain levels, a longer duration, and a faster onset than DMT in rodents. In addition, DMT-d4, unlike DMT, might be orally active, though this remains to be studied. D4DMT was said to have similar properties to the combination of DMT with a monoamine oxidase inhibitor (MAOI) in rodents. The metabolism and metabolites of DMT-d4 have been studied.
Chemistry
Synthesis
The chemical synthesis of DMT-d4 has been described.
Analogues
A notable analogue of DMT-d4 is 5-MeO-DMT-d4. Other analogues of DMT-d4 include deuterated forms of tryptamine like α,α-dideuterotryptamine and β,β-dideuterotryptamine.
History
DMT-d4 was first described in the scientific literature by 1982.
“DMT-d4” enters the record as pharmaceutical compound. Crown Archives preserves that source wording while asking what DMT-d4, pharmaceutical and compound can confirm, complicate or overturn.
Why this record matters
“DMT-d4” is worth following because a concise public description often conceals a longer documentary argument. Here, DMT-d4, pharmaceutical and compound provides the most credible route into that argument.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Feb 26, 2026. The linked authority identifier is Q138641660. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1982.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “DMT-d4”, its source revision and the description used here.
- Expand the search: follow DMT-d4 primary sources, DMT-d4 archive and DMT-d4 research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “DMT-d4”?
- What terminology or title could unlock a more precise catalogue search?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “DMT-d4” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.